nVision Medical Corp., a Mountain View, CA-based clinical-stage medical device company, raised $12m in Series B funding.
The round was led by new investor Arboretum Ventures (Ann Arbor, Michigan) with participation from Catalyst Health Ventures. Arboretum’s Tom Shehab, M.D. joined nVision’s Board of Directors in conjunction with the funding.
The company will use the funds for further product development, clinical studies, and regulatory submissions for its patented micro-catheter technology.
Led by Surbhi Sarna, Chief Executive Officer and President, nVision has developed a product that enables access to fallopian tubes to occur in the office of the gynecologist without any incisions or general anesthesia. Currently, the company has two areas of focus – utilizing micro-catheter technology for cell collection from the fallopian tube and for direct visualization of the fallopian tube lumen.
Earlier this year, nVision obtained the first FDA clearance for a device that collects cells from the fallopian tube and performed its First-in-Human case for a device that allows direct visualization of the fallopian tube.